Acadian Asset Management LLC Aeglea Bio Therapeutics, Inc. Transaction History

Acadian Asset Management LLC

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	BUY	$0.35 - $1.54 $322,988 - $1.42 Million	922,823 Added 196.95%	1,391,381 $625,000
Q3 2022 Nov 14, 2022	BUY	$0.38 - $0.81 $20,964 - $44,688	55,171 Added 13.35%	468,558 $245,000
Q2 2022 Aug 09, 2022	BUY	$0.5 - $2.66 $131,994 - $702,208	263,988 Added 176.7%	413,387 $208,000
Q1 2022 May 12, 2022	BUY	$1.87 - $4.77 $34,714 - $88,550	18,564 Added 14.19%	149,399 $342,000
Q4 2021 Feb 10, 2022	BUY	$3.5 - $8.42 $457,922 - $1.1 Million	130,835 New	130,835 $620,000
Q2 2019 Aug 08, 2019	SELL	$6.1 - $8.78 $52,277 - $75,244	-8,570 Closed	0 $0
Q1 2019 May 09, 2019	BUY	$7.6 - $9.4 $65,132 - $80,558	8,570 New	8,570 $69,000
Q4 2018 Feb 07, 2019	SELL	$6.51 - $10.19 $353,037 - $552,603	-54,230 Closed	0 $0
Q3 2018 Oct 30, 2018	SELL	$8.24 - $11.0 $155,488 - $207,570	-18,870 Reduced 25.81%	54,230 $519,000
Q2 2018 Jul 24, 2018	BUY	$7.87 - $10.89 $332,428 - $459,993	42,240 Added 136.88%	73,100 $773,000
Q1 2018 Apr 12, 2018	BUY	$5.07 - $10.9 $105,390 - $226,578	20,787 Added 206.36%	30,860 $307,000
Q4 2017 Jan 18, 2018	BUY	$4.0 - $5.98 $22,076 - $33,003	5,519 Added 121.19%	10,073 $54,000
Q3 2017 Oct 13, 2017	BUY	$2.91 - $4.93 $13,252 - $22,451	4,554	4,554 $22,000

241K

Ticker AGLE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 61,172,500
Market Cap $1.69B
Description
Aeglea BioTherapeutics, Inc., a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of patients and families with rare metabolic diseases. The company's lead product candidate is pegzilarginase, a recombinant human Arginase 1 that is in Phase III PEACE trial to evaluate the safety and efficacy f...

Get notified when there are updates to the investment portfolio of Acadian Asset Management LLC, based on Form 13F filings with the SEC.

Stay updated on Acadian Asset Management LLC with notifications on news.